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Abstract 49 
Evidence-based guidelines recommend exercise therapy for patients with chronic heart failure 50 
(CHF). Such patients have increased atherothrombotic risk. Exercise can transiently increase 51 
platelet activation and reactivity and decrease vascular function in healthy participants, 52 
although data in CHF is scant. Eccentric (ECC) cycling is a novel exercise modality which 53 
may be particularly suited to patients with CHF, but the acute impacts of ECC on platelet and 54 
vascular function are currently unknown. Our null hypothesis was that ECC and concentric 55 
(CON) cycling, performed at matched external workloads, would not induce changes in 56 
platelet or vascular function in patients with CHF. Eleven patients with heart failure with 57 
reduced ejection fraction (HFrEF) took part in discrete bouts of ECC and CON cycling. 58 
Before and immediately after exercise, vascular function was assessed by measuring diameter 59 
and flow mediated dilation (FMD) of the brachial artery. Platelet function was measured by 60 
the flow cytometric determination of glycoprotein IIb/IIIa activation and granule exocytosis 61 
in the presence and absence of platelet agonists. ECC increased baseline artery diameter (pre: 62 
4.0±0.8mm vs post: 4.2±0.7mm, P=0.04) and decreased FMD%. When changes in baseline 63 
artery diameter were accounted for the decrease in FMD post-ECC was no longer significant. 64 
No changes were apparent after CON. Neither ECC nor CON resulted in changes to any 65 
platelet function measures (all P>0.05). These results suggest both ECC and CON cycling at 66 
a moderate intensity and short duration can be performed by patients with HFrEF, without 67 
detrimental impacts on vascular or platelet function. 68 
  69 
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New and Noteworthy  70 
This is the first evidence to indicate that eccentric cycling can be performed relatively safely 71 
by patients with chronic heart failure, as it did not result in impaired vascular or platelet 72 
function compared to conventional cycling. This is important, as acute exercise can 73 
transiently increase atherothrombotic risk and eccentric cycling is a novel exercise modality 74 
that may be particularly suited to patients with chronic heart failure. 75 
 76 
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Introduction 80 
Chronic heart failure (CHF) occurs in approximately 10% of individuals aged over 65 years 81 
and is expected to rise significantly over the next decade (27). Chronic heart failure is 82 
characterized by abnormalities in cardiac structure and/or function, resulting in the inability 83 
of the heart to deliver sufficient blood and therefore oxygen to meet the metabolic demands 84 
of the body. Individuals with CHF experience impaired physical function (18) and have a 85 
greater risk of sudden thrombotic related events compared to healthy individuals (25). Such 86 
events include acute coronary syndromes and stroke, which occur in association with 87 
compromised vascular function and platelet mediated thrombosis (10, 22). Indeed, impaired 88 
vascular function (9, 26), increased platelet activation (39), and a hypercoagulable state (13) 89 
have been documented in patients with CHF. 90 
 91 
Exercise training is recommended as part of the management of CHF, to alleviate decline in 92 
health and physical function and to maintain quality of life (8, 32, 40). Whilst exercise is 93 
generally safe and regular exercise training decreases long term risk of cardiovascular events, 94 
acute coronary risk is increased during and immediately after participation in a bout of 95 
exercise (35). This may relate, in part, to the impact of some forms of exercise on vascular 96 
and/or platelet function. Some studies that have tested vascular function before and after 97 
acute exercise in healthy participants have revealed transient decreases after exercise (3, 7). 98 
The majority of such studies have been performed in healthy volunteers and involved 99 
conventional forms of aerobic exercise, with assessments of the brachial artery providing a 100 
surrogate for systemic vascular function. Platelet activation and reactivity to agonist exposure 101 
have also been reported to be elevated immediately following both moderate and high 102 
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intensity exercise in healthy participants (15, 19, 36). Currently there is little evidence 103 
regarding the impacts of distinct types of exercise on platelet or vascular function in CHF.   104 
 105 
It has been demonstrated in healthy participants, that eccentric (ECC) cycling can be carried 106 
out requiring less oxygen uptake compared to conventional concentric (CON) cycling (30). 107 
Recently, we provided evidence to suggest that ECC cycling may be a novel and beneficial 108 
exercise modality for patients with CHF, as matched exercise workloads can be performed at 109 
a lower metabolic demand than CON cycling (4). Few studies have addressed the acute 110 
impact of ECC exercise on either platelet or vascular function (31, 33). These studies, 111 
performed in separate groups of apparently heathy participants, have reported that ECC based 112 
resistance exercise did not increase platelet activation post-exercise (31), but did reduce flow 113 
mediated dilation (FMD) 1 hour post-exercise (33). To our knowledge, no previous study has 114 
investigated the acute impact of CON or ECC cycling on either platelets or vascular function 115 
in patients with CHF. The aim of this study was to therefore compare the impact of short 116 
bouts of ECC and CON cycling, matched for external workload, on platelets and vascular 117 
function in patients with CHF. Our null hypothesis was that both modalities would have no 118 
effects on either platelet or vascular function. 119 
 120 
Materials and Methods 121 
A comprehensive account of the recruitment and exercise protocols used in the present study 122 
can be found in our recently published paper, which focused on metabolic and hemodynamic 123 
outcomes (4). Briefly, patients with reduced left ventricular systolic function (ejection 124 
fraction <45%), New York Heart Association class I to III were recruited from the Advanced 125 
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Heart Failure and Cardiac Transplantation Unit at Fiona Stanley Hospital, Perth, Western 126 
Australia. Ethics approval for the study was provided by the Metro South Health Human 127 
Research Ethics Committee (HREC 14-160) and the Human Research Ethics Committee at 128 
The University of Western Australia. Exclusion criteria included: resting hypertension 129 
(>165/95 mmHg), severe obstructive aortic stenosis, severe rhythm disorders that would 130 
exclude safe participation in exercise, severe pulmonary hypertension (systolic >70 mmHg), 131 
venous thromboembolic history within the past three months, musculoskeletal comorbidity 132 
limiting functional capacity beyond the effect of CHF. Patients continued their routine 133 
medical therapy throughout the study period.  134 
 135 
A power calculation was conducted a priori using (G* Power 3.1.9.2 Software) using data 136 
from platelet function assays conducted in our lab, indicating that based on power of 80% and 137 
a standard deviation of 5%, 10 participants would be sufficient to detect a change of 5% at a 138 
significance level of P = <0.05 (11). This was supported by a previously published study 139 
(31).  140 
 141 
Maximal Exercise Test 142 
In an initial session, participants performed a maximal graded exercise test on a recumbent 143 
bicycle ergometer (Corival, Lode BV, Groningen, Netherlands), with power output increasing 144 
20 watts (W) every 3 minutes until volitional exhaustion. The maximal power output (W) 145 
achieved during this test was used to prescribe the exercise intensity of subsequent sessions.  146 
 147 
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General Protocol 148 
To ensure no recent changes were made in relation to participants symptoms, medications, 149 
alcohol use and physical activity habits, participants were asked a series of questions relating 150 
to this on arrival to the laboratory of each session. The participant sat on the recumbent 151 
cycling ergometer that was to be used on that particular day (i.e., ECC or CON) and rested 152 
for 10 minutes, after which a venous blood sample was collected. Following another 5 153 
minutes of seated rest, baseline brachial artery diameter and an FMD test were performed on 154 
the left arm. The participant then began the exercise protocol (see protocol below). 155 
Immediately following the brief cool-down aspect of cycling, a blood sample was taken from 156 
the right arm, and vascular tests were performed simultaneously on the left arm. Both the 157 
CON and ECC bicycle ergometers were recumbent based apparatus, ensuring body positions 158 
were identical for both modalities. Whilst the time of day at which the laboratory visits were 159 
conducted varied between participants, it was maintained at the same time within 160 
participants. 161 
 162 
Eccentric Cycling (ECC) 163 
Seven days following the maximal bicycle ergometer test, participants underwent the ECC 164 
protocol. This was performed on a recumbent ergometer (Eccentric Trainer, Metitur, Ltd, 165 
Jyväskylä, Finland) with a 1.5 kW motor that powered the cranks in reverse. Participants then 166 
performed 11 minutes of continuous ECC cycling, maintaining a cadence of 40 rpm 167 
throughout. This was composed of a 3 minute warm-up aiming to achieve 30% Wmax, 5 168 
minutes at 70% Wmax and 3 minutes of active recovery with no resistance. As external 169 
workload during ECC cycling is difficult to maintain constant, the watts performed was 170 
documented every 10 seconds, and this was used to match the intensity for CON cycling.  171 
8 
 
 172 
Concentric Cycling (CON) 173 
After a further seven days, participants underwent the CON protocol, which was performed at 174 
the same time of day as the ECC protocol. CON cycling was performed on the same 175 
recumbent bicycle as the maximal exercise test. The total exercise duration, warm-up, main 176 
component, active recovery and cadence were identical to that described above for ECC. 177 
However, the intensity (watts) of CON was changed manually by a researcher every 30 178 
seconds to match the intensity performed during ECC for each individual subject.  179 
 180 
Blood Samples 181 
A venous blood sample was collected from the antecubital fossa with no stasis using a 21G 182 
winged needle set (Greiner bio-one, Kremsmuenster, Austria). The first 2 mL was collected 183 
into a non-additive discard tube, followed by a 4 mL 3.2% sodium citrate tube (Vacuette by 184 
Greiner bio-one, Kremsmuenster, Austria).  185 
 186 
Platelet Function Tests 187 
Platelet function was measured by flow cytometric determination of glycoprotein IIb/IIIa 188 
activation (measured by PAC-1 binding) and granule exocytosis (measured by surface 189 
CD62P expression), in the presence and absence of platelet agonists according to recent 190 
recommendations (23). Within ten minutes of collection, whole blood from the sodium citrate 191 
tube was diluted 1:5 with HEPES saline buffer and incubated for exactly 15 minutes in a 192 
cocktail of three fluorescent conjugated antibodies. These included: CD42b PE-Cy5 (platelet 193 
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identifier), PAC-1 fluorescein (FITC) and anti-CD62P phycoerythrin (PE), or isotype control 194 
IgG1Κ PE (all BD Pharmingen, San Diego, CA). Seven reaction tubes (1.5 mL Protein 195 
LoBind, Eppendorf, Germany) were used for platelet immunophenotyping which included: 196 
isotype control, positive control (250 µM thrombin receptor activating peptide-6, TRAP 197 
[SFLLRN, Sigma-Aldrich, MO]), no agonist, TRAP 2 µM, adenosine diphosphate (ADP) 1.5 198 
µM (Chrono-Log Corp., PA), arachidonic acid AA 10 µg/mL (Sodium arachidonate, 199 
Bio/Data Corp., PA) and collagen 1.5 µg/mL (Chrono-Log Corp., PA). Samples were 200 
incubated at room temperature with the exception of tubes containing AA and collagen, 201 
which were incubated at 37°C using a dry block heater (Ratek DBH20D, Victoria, Australia). 202 
Following 15 minutes of incubation, samples were fixed with stabilizing fixative (Becton 203 
Dickinson), stored at 4°C and were analyzed within 24 hours by flow cytometry (BD 204 
FACSCanto II) at a low flow rate. For each reaction tube, 10,000 platelet positive events 205 
were counted and single stained compensation beads were utilized to account for spectral 206 
overlap between the three fluorophores (BD Biosciences). ADP at the concentration used (1.5 207 
µM) caused maximal PAC-1 binding in all participants, so was not included in statistical 208 
analysis.  209 
 210 
Vascular function tests 211 
The vascular assessments were conducted in a quiet, temperature-controlled room in 212 
accordance to recent guidelines (34). In brief, to examine baseline brachial artery diameter 213 
and FMD, the non-dominant arm was extended and positioned at an angle of ~80° from the 214 
torso. A rapid inflation and deflation pneumatic cuff (D.E. Hokanson, Bellevue, WA, USA) 215 
was positioned on the forearm, immediately distal to the olecranon process to provide a 216 
forearm ischemia stimulus. A 10-MHz multi-frequency linear array probe, attached to a high-217 
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resolution ultrasound machine (T3200; Terason, Burlington, MA, USA) was used to image 218 
the brachial artery in the distal 1/3rd of the upper arm. When an optimal image was obtained, 219 
the probe was held stable and the ultrasound parameters were set to optimize the longitudinal, 220 
B-mode images of lumen–arterial wall interface. Continuous Doppler velocity assessments 221 
were also obtained using the ultrasound, and were collected using the lowest possible 222 
insonation angle (always <60°). Following a 1 minute baseline recording of brachial artery 223 
diameter and velocity (Camtasia Studio 8, TechSmith, Okemos, MI), the forearm cuff was 224 
inflated (220 mmHg) for 5 min. Diameter and flow recordings resumed 30 seconds prior to 225 
cuff deflation and continued for 3 minutes thereafter. Post-test analysis of brachial artery 226 
diameter was performed using custom-designed edge-detection and wall-tracking software, 227 
which is largely independent of investigator bias (38). Brachial artery FMD is presented as 228 
relative (%) rise from the preceding baseline diameter. We have shown that the 229 
reproducibility of diameter measurements using this semi-automated software is significantly 230 
better than manual methods, reduces observer error significantly, and possesses an intra-231 
observer CV of 6.7% (37). 232 
 233 
Statistics 234 
Statistical analyses were performed using SPSS 22 (IBM, Armonk, NY) software. For data 235 
meeting the assumptions of parametric statistical tests, paired t-tests were conducted to 236 
determine if significant changes occurred within each session over time. For data failing the 237 
assumptions of parametric tests, Wilcoxon signed rank tests were conducted. Subsequently, 238 
for results revealing a significant change in FMD% post-exercise, a linear mixed model 239 
analysis was conducted with logarithmically transformed artery diameter. This procedure 240 
accounts for changes in baseline diameter and is appropriate under such circumstances (1).  241 
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 242 
Results 243 
Eleven participants (9 male) (mean ± SD) age: 52.0 ± 9.3 yrs, height 178.5 ± 9.3 cm, body 244 
mass 91.6 ± 19.6 kg, V̇O2 peak 19.9 ± 4.0 ml.kg.min-1 completed the study. The medication use 245 
of participants is presented in Table 1. Due to complications with the vascular data files of 246 
one participant, ten participants were included in the analysis of peripheral vascular function. 247 
Most of these participants were the same as those included in our recent manuscript related to 248 
oxygen consumption and hemodynamic variables (4). Briefly, this paper revealed that ECC 249 
cycling can be performed at matched external workloads, but lower V̇O2, minute ventilation 250 
and respiratory exchange ratio compared to CON cycling. 251 
 252 
Vascular function 253 
ECC cycling resulted in a significant (P = 0.04) increase in baseline artery diameter from pre- 254 
(4.0 ± 0.8 mm) to post-exercise (4.2 ± 0.7 mm) (see Figure 1). No change (P = 0.43) was 255 
observed in baseline artery diameter after CON (pre 4.0 ± 0.7 mm vs post 4.0 ± 0.7 mm). No 256 
significant difference (P = 0.18) in peak artery diameter was observed between pre- (4.4 ± 0.8 257 
mm) and post-exercise (4.5 ± 0.7 mm) for ECC, as well as CON (P = 0.53, pre 4.3 ± 0.7 mm 258 
vs post 4.4 ± 0.7 mm).  259 
 260 
ECC cycling resulted in a significant (P = 0.05) decrease in FMD% from pre- (9.0 ± 2.9 %) 261 
to post-exercise (6.0 ± 4.0 %) when changes in baseline diameter (ie changes in the baseline 262 
pre to post ECC bout) were not accounted for (Figure 2A). CON cycling did not result in any 263 
change (P = 0.94) in FMD% (pre: 8.8 ± 2.8 % vs post: 8.8 ± 3.9 %). When the FMD response 264 
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was corrected to account for changes in baseline diameter as a result of the exercise bout 265 
(Figure 1), the change in FMD post-ECC was no longer significant (P = 0.26), as shown in 266 
Figure 2 (panel B). This suggests the decrease in FMD following ECC was due, at least in 267 
part, to the increase in baseline artery diameter following ECC. No significant change was 268 
found for time to peak brachial artery diameter for ECC (pre: 68.9 ± 34.0 sec vs post: 77.5 ± 269 
23.3 sec, P = 0.55) or CON (pre: 68.4 ± 26.1 sec vs post: 66.6 ± 27.9 sec, P = 0.64).    270 
 271 
Platelet Function  272 
No significant differences (all P = >0.05) were found in either PAC-1 (see Table 2) or anti-273 
CD62P binding (see Table 3) in the absence or presence of canonical platelet agonists 274 
following CON or ECC cycling. 275 
 276 
Discussion 277 
Acute bouts of exercise involve a transient elevation in the risk of an acute cardiovascular 278 
event (35). This may be associated with evidence suggesting that some forms of acute 279 
exercise can reduce indices of vascular function (7) and increase platelet activation and 280 
sensitivity to agonists (15, 19). This is the first study, to our knowledge, to investigate the 281 
acute effect of discrete bouts of CON and ECC cycling, matched for duration and external 282 
workload, on platelet and brachial artery vascular function in patients with HFrEF. We 283 
assessed the impacts of ECC exercise because it may be particularly relevant in HFrEF, since 284 
it requires less oxygen uptake to sustain matched workloads of exercise (30). We found that 285 
ECC cycling significantly increased conduit artery diameter, with no such change observed 286 
following CON cycling. The decrease in brachial FMD observed following ECC may, at least 287 
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partly, have been caused by this significant increase in baseline artery diameter post-exercise, 288 
as FMD corrected for changes in baseline diameter was not significantly altered by exercise. 289 
This does not exclude the possibility that the changes in FMD% were attributable to the 290 
impact of ECC on vasodilator function, but it is appropriate to consider baseline diameter 291 
effects on the interpretation of FMD% responses (1).  292 
 293 
The vasodilator impact of ECC on baseline arterial diameter occurred despite the workload 294 
being matched to the CON condition, with the ECC session performed with ~13% lower V̇O2 295 
requirement (4).  Participation in short bouts of CON and ECC cycling at a moderate intensity 296 
did not result in any significant change in platelet activation, as measured by PAC-1 or anti-297 
CD62P binding, both of which are sensitive and specific markers of platelet function 298 
associated with acute coronary risk (24). These findings suggest that short bouts of moderate 299 
intensity ECC or CON cycling have no significant detrimental impacts on vascular or platelet 300 
function in patients with HFrEF. 301 
 302 
Eccentric exercise is an appealing modality of exercise for patients with impaired cardiac and 303 
hemodynamic function, and we have recently demonstrated that ECC cycling is associated 304 
with a lower oxygen demand than conventional CON cycling in patients with HFrEF (4). 305 
Exercise prescription in heart failure is often challenging, given the extreme deconditioning 306 
that characterizes the disease. A form of exercise, such as ECC, which allows greater 307 
intensities of exercise to be undertaken at a lower relative systemic burden, should 308 
theoretically enhance the benefits of training.  However, the acute effects of ECC cycling on 309 
peripheral vascular and platelet function, both of which may have implications relating to 310 
acute atherothrombotic risk, have not previously been explored in HFrEF. Indeed, acute ECC 311 
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exercise data in patients with CHF are sparse, but one study suggests that eccentric resistance 312 
exercise decreased brachial FMD post-exercise, even after adjustment for baseline diameter 313 
changes (33). This contrasts somewhat with our findings which suggest an increase in arterial 314 
function post-ECC, characterized by baseline vasodilation which impacted upon the FMD 315 
result. Decreases in FMD need to be considered with caution in cases where significant 316 
changes in the baseline diameter have occurred, as we have previously explained (1). It has 317 
also been demonstrated that post-exercise changes in FMD are dependent on exercise 318 
intensity, with higher intensities conferring greater reduction (3), and we cannot rule out the 319 
possibility that exercise performed at a different intensity or for longer duration, may have 320 
resulted in a different outcome.  321 
 322 
The primary difference in brachial artery response between the cycling modalities was an 323 
increase in resting vessel diameter following ECC. No such change was evident following 324 
CON. The underlying mechanisms behind this are unknown, but may be linked to differences 325 
in hemodynamics, neural and hormonal responses between these contrasting exercise 326 
modalities (2). We recently reported that heart rate, mean arterial pressure and rate pressure 327 
product are similar between the ECC and CON cycling (4), implying that differences in 328 
hemodynamics are not likely to account for the vasodilator effect of ECC. It is well 329 
established that hemodynamic effects such as those associated with increased shear stress, 330 
transmural wall pressure and heart rate can directly modify artery function (14). Whilst the 331 
mechanisms responsible for the dilator effect of ECC are not currently known, our findings 332 
suggest that moderate intensity, short duration ECC exercise does not adversely impact on 333 
vascular function in HFrEF. 334 
 335 
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There were no significant changes in circulating activated platelets, or platelet reactivity to 336 
physiologically relevant agonists, following either exercise protocol. A previous study in 337 
healthy, untrained participants observed that the acute effect of exercise on platelets is 338 
intensity dependent (16), and it is possible that the intensity and/or duration of exercise used 339 
in the present study were insufficient to induce significant changes in platelet function. This 340 
may also explain why our findings contrast with a previous study that reported increased 341 
platelet activation following a maximal CON cycling exercise test in CHF (5). ECC exercise 342 
is not commonly prescribed to patients with CHF and the acute impacts of ECC on platelets 343 
have not previously been reported in such participants. Whilst the exercise protocols included 344 
in the present study were somewhat conservative, in part to reduce the risk of skeletal muscle 345 
damage and soreness (20, 29), our findings suggest that ECC cycling can be conducted 346 
acutely in patients with HFrEF, without the risk of inducing significant platelet activation. 347 
We cannot comment on the possible detrimental effects of ECC performed at higher 348 
intensities than those used in the present experiment. 349 
 350 
Participants were undergoing treatment for HFrEF throughout the study period, and were 351 
instructed to maintain their normal regimen of medication, so not to impact upon their 352 
therapy. As such, ~63% of participants were prescribed some form of anti-353 
platelet/coagulation medication, and it is possible this may have masked any effect of 354 
exercise on platelets in the present study. However, there is evidence to suggest this may not 355 
be the case, as aspirin and warfarin use have previously shown to be incapable of inhibiting 356 
the effects of maximal exercise on platelets and coagulation markers (6, 17, 21). Another 357 
important limitation of this study was that the ECC session had to precede the CON session 358 
in all cases, so that we could closely and accurately match the exercise intensities. Because 359 
these sessions were not randomized, we cannot exclude the possibility of an order effect, but 360 
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the sessions were separated by a minimum of 7 days in an attempt to avoid this problem. 361 
Finally, it is germane to emphasize that our study of the acute effect of exercise cannot not be 362 
directly extrapolated to a chronic adaptation. Although, logically, repetition of acute 363 
responses should lead to adaptation, the nature and direction of such training-induced 364 
adaptation may differ from changes seen in response to acute bouts of exercise. This concept 365 
been captured in the term “hormesis” (12, 28), taken in this context to indicate that repetitive 366 
episodic exposure to stimuli that challenge and compromise function, may lead to 367 
upregulation and enhancement in chronic responses. In the present study, we did not observe 368 
large responses, either positive or negative, in terms of platelet function, but that does not 369 
necessarily mean that training studies will not reveal adaptation.  370 
 371 
In summary, we observed a relative vasodilator impact of ECC cycling, but not after CON 372 
cycling in patients with HFrEF, however platelet function was unaffected after both 373 
exercises. Given that both platelet and vascular function are involved in acute coronary 374 
syndromes, our findings provide novel data relating to the impact of ECC cycling in patients 375 
with HFrEF, and do not suggest that ECC cycling has greater acute impacts on patients with 376 
HFrEF than conventional cycling, when matched for external workload and duration. While 377 
the acute effects on vascular function of the brachial artery and platelet activation of ECC 378 
exercise do not differ from concentric cycling, future studies will be required before 379 
recommendations can emerge regarding the adoption of ECC cycling in routine HFrEF 380 
training programs.  381 
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Figure Caption   529 
 530 
Figure 1. Changes in brachial artery diameter before and immediately after concentric 531 
(CON) and eccentric (ECC) cycling (A), delta change in artery diameter from pre- to post-532 
exercise time-points (B), individual response changes in baseline diameter during CON (C) 533 
and ECC cycling (D). N=10. Data in Panels A and B are mean ± SE, * indicates significant 534 
difference from pre-exercise (P = 0.04). 535 
 536 
 537 
Figure 2. Change in flow mediated dilation (FMD%) from pre- to post-concentric (CON) and 538 
eccentric (ECC) cycling when not adjusted for baseline diameter changes (A), and when 539 
adjusted for baseline diameter change (B). Individual responses in FMD (unadjusted for 540 
baseline diameter) pre and post CON (C) and ECC cycling (D). N=10. Data in Panels A and 541 
B are mean ± SE, * indicates significant difference from pre-exercise (P = 0.05). 542 
  543 
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Table 1. Medication use of participants  
Medication  
Anti-platelet (total) 
        Aspirin 
        Warfarin 
        Rivaroxaban 
        Prasugrel 
ACE Inhibitors (total) 
        Ramipril 
        Perindopril 
β-Blockers (Bisoprolol) 
Statins (Atorvastatin) 
Anti-arrhythmic (Amiodarone) 
Aldosterone receptor antagonist 
Angiotensin II receptor antagonist 
N (%) 
7 (63.6) 
3 (27.3) 
4 (36.4) 
2 (18.2) 
1 (9.1) 
9 (81.8) 
8 (72.7) 
1 (9.1) 
9 (81.8) 
7 (63.6) 
4 (36.4) 
4 (36.4) 
1 (9.1) 
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Table 6.2 Platelet PAC-1 binding before and after concentric and 
eccentric cycling 
Variable   % PAC-1 binding 
                                       
No Agonist 
Concentric 
Eccentric 
 
TRAP 2 µM 
Concentric 
Eccentric 
 
AA 10 µg/ml 
Concentric 
Eccentric 
 
Collagen 1.5 µg/ml 
Concentric 
Eccentric 
Pre 
 
6.8 ± 5.2 
4.7 ± 0.8 
 
 
25.1 ± 3.6 
23.7 ± 3.6 
 
 
29.0 ± 3.3 
24.8 ± 3.0 
 
 
14.7 ± 2.0 
11.7 ± 1.5 
Post 
 
5.6 ± 2.2 
5.2 ± 0.9 
 
 
22.8 ± 1.8 
23.3 ± 3.5 
 
 
25.1 ± 3.1 
22.3 ± 2.8 
 
 
11.4 ± 1.2 
  9.9 ± 1.6 
Statistics 
 
P = 0.859 
P = 0.213 
 
 
P = 0.450 
P = 0.594 
 
 
P = 0.104 
P = 0.284 
 
 
P = 0.091 
P = 0.178 
Thrombin Receptor Activating Peptide-6 TRAP, Arachidonic Acid 
AA 
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Table 6.3 Platelet anti-CD62P binding with concentric and 
eccentric cycling 
Variable % anti-CD62P binding                   
                                       
No Agonist 
Concentric 
Eccentric 
 
TRAP 2 µM 
Concentric 
Eccentric 
 
ADP 1.5 µM 
Concentric 
Eccentric 
 
AA 10 µg/ml 
Concentric 
Eccentric 
 
Collagen 1.5 µg/ml 
Concentric 
Eccentric 
Pre 
 
 2.0 ± 0.9 
 1.8 ± 1.3 
 
 
 5.5 ± 3.5 
 5.3 ± 4.5 
 
 
69.1 ± 25.0 
69.4 ± 26.3 
 
 
12.2 ± 6.1  
13.2 ± 6.6 
 
 
  5.1 ± 4.4 
  5.3 ± 4.8 
Post 
 
  2.6 ± 1.0 
  2.0 ± 1.4 
 
 
  5.9 ± 3.8 
  6.3 ± 5.1 
 
 
68.9 ± 27.9 
71.8 ± 26.0 
 
 
13.7 ± 8.1 
13.2 ± 6.1 
 
 
  6.1 ± 6.6 
  5.1 ± 4.9 
Statistics 
 
P = 0.450 
P = 0.169 
 
 
P = 0.374 
P = 0.213 
 
 
P = 0.722 
P = 0.450 
 
 
P = 0.398 
P = 0.981 
 
 
P = 0.213 
P = 0.712 
Thrombin Receptor Activating Peptide-6 TRAP, Adenosine 
diphosphate ADP, Arachidonic Acid AA 
